NewEdge Wealth LLC Makes New Investment in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• NewEdge Wealth purchased 11,326 Zimmer Biomet shares in the second quarter, worth approximately $975,000. Institutional investors and hedge funds collectively own 88.89% of the company.
• Analyst sentiment remains mixed, with an overall “Hold” rating and an average price target of $104.42. Targets range from $93 to $110, while recent ratings included a downgrade to “Strong Sell” and an upgrade to “Outperform.”
• Zimmer Biomet exceeded quarterly expectations, reporting $2.07 in adjusted EPS and $2.18 billion in revenue, with revenue up 4.8% year over year. The company issued fiscal 2026 EPS guidance of $8.47 to $8.59.

NewEdge Wealth LLC bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 11,326 shares of the medical equipment provider's stock, valued at approximately $975,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $204,000. Sivia Capital Partners LLC bought a new position in Zimmer Biomet in the second quarter valued at approximately $232,000. United Bank raised its position in Zimmer Biomet by 10.7% during the second quarter. United Bank now owns 11,896 shares of the medical equipment provider's stock valued at $1,085,000 after purchasing an additional 1,153 shares in the last quarter. Federated Hermes Inc. raised its position in Zimmer Biomet by 129.2% during the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider's stock valued at $194,000 after purchasing an additional 1,202 shares in the last quarter. Finally, Cerity Partners LLC lifted its stake in Zimmer Biomet by 93.6% during the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider's stock worth $7,004,000 after purchasing an additional 37,116 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ZBH shares. Zacks Research lowered Zimmer Biomet from a "hold" rating to a "strong sell" rating in a research note on Monday, July 27th. Weiss Ratings raised Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Tuesday, August 4th. JPMorgan Chase & Co. reduced their price objective on Zimmer Biomet from $100.00 to $95.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 29th. Royal Bank Of Canada boosted their target price on Zimmer Biomet from $101.00 to $110.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. Finally, Citigroup dropped their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a "neutral" rating for the company in a report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $104.42.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.28% of the company's stock.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $101.01 on Friday. The firm's fifty day moving average price is $92.64 and its two-hundred day moving average price is $91.00. The stock has a market cap of $19.27 billion, a PE ratio of 24.58, a PEG ratio of 2.69 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $108.29.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company had revenue of $2.18 billion during the quarter, compared to analysts' expectations of $2.13 billion. During the same period in the prior year, the company earned $2.07 EPS. Zimmer Biomet's revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source